Optimizing Patient Selection for Semaglutide Treatment in Weight Management Across Binge Eating Patterns

What This Trial Is About

Researchers are investigating how GLP-1 receptor analogs like semaglutide Wegovy affect eating behavior, binge eating, and weight control through the gut-brain axis. This study aims to determine which individuals benefit most from semaglutide treatment across the spectrum of binge eating. The trial focuses on adults with obesity or overweight conditions and evaluates the treatments impact on body mass index and binge eating severity. Participants will receive semaglutide injections once weekly, starting at 0.25 mg with dose increases every four weeks up to 2.4 mg or the highest tolerated dose. The treatment period lasts six months, during which participants attend 2 to 4 clinic visits for checkups and tests. Throughout the study, they will wear a smartwatch and complete questionnaires on their smartphones to monitor behaviors and responses. During the trial, participants will undergo assessments including body mass index measurements and Binge Eating Scale evaluations before and after treatment. The study team will track changes from enrollment to the end of the six-month treatment. Safety and adherence are monitored through clinic visits and digital tools. The total participation length is six months, ending with outcome evaluations related to weight and eating behavior.

A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating Spectrum